---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-087574"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2023-08-04T23:59:59+00:00"
generated_at: "2026-06-12T06:20:42.821093+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# TransCode Therapeutics faces Nasdaq delisting after compliance plan rejected; hearing set for Oct 2023

## Summary
- Nasdaq rejected compliance plan on July 26, 2023, for failing to meet $2.5M stockholders' equity requirement.
- Company appealed; oral hearing before Nasdaq Hearings Panel scheduled for October 2023.
- Delisting action stayed until hearing held and final written decision issued.
- No assurance that plan will be accepted or that compliance can be regained.

## SEC filing metadata
- accession: 0001104659-23-087574
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2023-08-04T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465923087574/0001104659-23-087574-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465923087574/tm2322857d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-087574
- JSON: https://secwatch.observer/filing/0001104659-23-087574.json
- Plain text: https://secwatch.observer/filing/0001104659-23-087574.txt

## Key facts
- Listing & Compliance Notices
  Transcode Therapeutics, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5815(a)(2)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: stockholders equity
  - Rules: 5815(a)(2)
  source text: that the Staff had determined not to accept the Company’s Compliance Plan, that the Company’s request for an extension had been denied, and that the Company’s common stock was subject to delisting from the Nasdaq Capital Market (the “Delisting Determination”). In accordance with Nasdaq Listing Rule 5815(a)(2), the Company was provided with seven calendar days, or until August 2, 2023, to request a hearing before the Nasdaq Hearings Panel (the “Panel”) to appeal the Delisting Determination. The Company subsequently submitted a request for a hearing to Nasdaq, and on August 2, 2023, was notified
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829635/000110465923087574/0001104659-23-087574-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.